|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007120,
umls-concept:C0033325,
umls-concept:C0036525,
umls-concept:C0205210,
umls-concept:C0854988,
umls-concept:C0871261,
umls-concept:C1522484,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1707455,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1992-2-27
|
|
pubmed:abstractText |
Between 1975 and 1985, 25 patients with metastatic bronchioloalveolar carcinoma and 223 patients with metastatic adenocarcinoma of the lung received experimental cisplatin-based chemotherapy at the Mayo Clinic. The chemotherapeutic response rates were 32% and 33%, respectively. The median times to progression of disease were identical (3 months in both groups). The median survival times were 4 months and 6 months, respectively. Metastatic bronchioloalveolar carcinoma is an aggressive disease that is associated with a poor prognosis, similar to metastatic adenocarcinoma of the lung.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0025-6196
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
27-32
|
|
pubmed:dateRevised |
2007-10-29
|
|
pubmed:meshHeading |
pubmed-meshheading:1310129-Adenocarcinoma,
pubmed-meshheading:1310129-Adenocarcinoma, Bronchiolo-Alveolar,
pubmed-meshheading:1310129-Adult,
pubmed-meshheading:1310129-Age Factors,
pubmed-meshheading:1310129-Aged,
pubmed-meshheading:1310129-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1310129-Cisplatin,
pubmed-meshheading:1310129-Cyclophosphamide,
pubmed-meshheading:1310129-Doxorubicin,
pubmed-meshheading:1310129-Female,
pubmed-meshheading:1310129-Humans,
pubmed-meshheading:1310129-Lomustine,
pubmed-meshheading:1310129-Lung Neoplasms,
pubmed-meshheading:1310129-Lymphatic Metastasis,
pubmed-meshheading:1310129-Male,
pubmed-meshheading:1310129-Mediastinal Neoplasms,
pubmed-meshheading:1310129-Methotrexate,
pubmed-meshheading:1310129-Middle Aged,
pubmed-meshheading:1310129-Mitomycin,
pubmed-meshheading:1310129-Pleural Neoplasms,
pubmed-meshheading:1310129-Prednisone,
pubmed-meshheading:1310129-Prognosis,
pubmed-meshheading:1310129-Remission Induction,
pubmed-meshheading:1310129-Risk Factors,
pubmed-meshheading:1310129-Sex Factors,
pubmed-meshheading:1310129-Survival Rate,
pubmed-meshheading:1310129-Triazines,
pubmed-meshheading:1310129-Vincristine,
pubmed-meshheading:1310129-Weight Loss
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Metastatic bronchioloalveolar carcinoma and metastatic adenocarcinoma of the lung: comparison of clinical manifestations, chemotherapeutic responses, and prognosis.
|
|
pubmed:affiliation |
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
